Literature DB >> 17110810

Optimizing early prediction for antipsychotic response in schizophrenia.

Yue-Cune Chang1, Hsien-Yuan Lane, Kung-Han Yang, Chieh-Liang Huang.   

Abstract

OBJECTIVE: Researchers, by studying first-generation antipsychotics, have established an early prediction model, which had a favorable specificity but a low sensitivity. This study aims to optimize early prediction of treatment response for schizophrenia using a novel statistic method that can be done even under the Microsoft Excel system of a personal computer.
METHODS: One hundred twenty-three inpatients with acutely exacerbated schizophrenia were given optimal therapy of risperidone, a commonly used second-generation antipsychotic agent. Response was defined as a reduction of 20% or more in the Positive and Negative Syndrome Scale total score. We applied the generalized estimating equation method's logistic regression to establish an early prediction model based on the treatment results of the first and the second weeks.
RESULTS: The proposed method correctly predicted nonresponse at 4 and 6 weeks in 80.8% and 81.8% of the patients, respectively. The method also identified responder at 4 and 6 weeks in 80.0% and 82.8%, respectively. The predictive powers (or correct prediction rates) at 4 and 6 weeks were 80.3% and 82.4%, respectively. In addition, the results based on the responses in Positive and Negative Syndrome Scale scores were slightly better than those in Brief Psychiatric Rating Scale scores.
CONCLUSIONS: Using the first 2 weeks' treatment results to predict the fourth or sixth week's treatment response is acceptable in terms of specificity, sensitivity, and predictive power. Further studies are needed. Moreover, whether this model could be applied to establish a prediction system for other psychotropics, such as antidepressants, also deserves research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110810     DOI: 10.1097/01.jcp.0000246211.95905.8c

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Unanswered questions in schizophrenia clinical trials.

Authors:  John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

3.  Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

Authors:  Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter
Journal:  Schizophr Bull       Date:  2008-01-08       Impact factor: 9.306

4.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

5.  Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.

Authors:  Islam R Younis; Mathangi Gopalakrishnan; Mitchell Mathis; Mehul Mehta; Ramana Uppoor; Hao Zhu; Tiffany Farchione
Journal:  JAMA Psychiatry       Date:  2020-10-01       Impact factor: 21.596

6.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 7.  Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.

Authors:  Christoph Hiemke
Journal:  Eur J Clin Pharmacol       Date:  2008-01-15       Impact factor: 2.953

Review 8.  Pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

Review 9.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Authors:  Christoph U Correll; Taishiro Kishimoto; John M Kane
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

10.  Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Allen W Nyhuis; Douglas E Faries; Bruce J Kinon; Robert W Baker; Anantha Shekhar
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.